Southeastern Clinical Research Institute (SCRI) is an independent clinical research organization based in Augusta, Georgia, specializing in conducting Phase IB-IV clinical trials. Established in 2005, the institute focuses on therapeutic areas including chronic kidney disease, cardiovascular disease, diabetes, and immunology.
SCRI operates as a dedicated research site, partnering with pharmaceutical and biotech companies to facilitate the development of novel medications. The organization is located in the heart of Augusta's medical district and maintains a robust infrastructure for patient recruitment, trial management, and data collection.
CLASSIFICATION
SIZE & FINANCIALS
Employees:1-50
Founded:2005
Ownership:private
Status:operating
PIPELINE
Stage:Commercial
Lead Drug Stage:N/A (Clinical Research Site)
Active Trials:100
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:AstraZeneca (ZENITH-CKD trial), Eli Lilly and Company, Calliditas Therapeutics AB, Bayer, KBP BioSciences
COMPETITION
Position:Niche Player
LINKS
Website:scri.care
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Southeastern Clinical Research Institute and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Southeastern Clinical Research Institute. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.